The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1758-1766

  Kornblau, Steven M ^a   Thall, Peter F ^a   Estrov, Zeev ^a   Walterscheid, Monica ^a   Patel, Shilpen ^a   Theriault, Alexandra ^a   Keating, Michael J ^a   Kantarjian, Hagop ^a   Estey, Elihu ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032781923     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Rowan, S., and Fisher, D. E. Mechanisms of apoptotic cell death. Leukemia (Baltimore), 11: 457-465, 1997.
2. Lotem, J., and Sachs, L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia (Baltimore), 10: 925-931, 1996.
3. Kroemer, G. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat. Med., 3: 614-620, 1997.
4. Cohen, G. M. Caspases: the executioners of apoptosis. Biochem. J., 326: 1-16, 1997.
5. Banker, D., Willman, C., Groudine, M., and Appelbaum, F. Cell cycle arrest and therapeutic sensitivity in de nova AML. Blood, 90 (Suppl. 1): 67a, 1997.
6. Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak M. L., Chen, I-M., Head, D. R., Appelbaum, F. R., and Willman, C. L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89: 3323-3329, 1997.
7. Konopleva, M., Zhao, S., Xie, Z., Seagall, H., Younes, A., Claxton, D. F., Estrov, Z., Kornblau, S. M., and Andreeff, M. Apoptosis. Molecules and mechanisms. In: A. J. P. Veerman, R. Pieters and G. J. L. Kaspers (eds.), Drug Resistance in Leukemia and Lymphoma III. Amsterdam: Plenum, in press, 1999.
8. Pan, G., Humke, E. W., and Dixit, V. M. Activation of caspases triggered by cytochrome c in vitro. FEBS Lett., 426: 151-154, 1998.
9. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.
10. Maung, Z. T., MacLean, F. R., Reid, M. M., Pearson, A. D. J., Proctor, S. J., Hamilton, P. J., and Hall, A. G. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br. J. Haematol., 88: 105-109, 1994.
11. Campos, L., Rouault, J-P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J-P., and Guyotat, D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response in chemotherapy. Blood, 81: 3091-3096, 1993.
12. Lauria, F., Raspador, D., Rondelli, D., Ventura, M. A., Facchini, M., Visani, G., Forconi, F., and Tura, S. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia (Baltimore), 11: 2075-2078, 1997.
13. Karakas, T., Maurer, U., Weidmann, E., Miething, C. C., Hoelzer, D., and Bergmann, L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol., 9: 159-165, 1998.
14. Estey, E. H., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., Kornblau, S., Pierce, S., Freireich, E. J., Deisseroth, A., and Keating, M. Use of G-CSF before, during and after fludarabine + ara-C induction therapy in newly-diagnosed AML or MDS: comparison with fludarabine + ara-C without G-CSF. J. Clin. Oncol., 12: 671-678, 1994.
15. Estey, E. H., Andreeff, M., O'Brien, S., and Kantarjian, H. Treatment of newly diagnosed acute promyelocytic leukemia (APL) without 1-β-D-arabinofuranosylcytosine (ara-C). Blood, 10: 266a-266a, 1996.
16. Kornblau, S. M., Xu, H-J., Zhang, W., Hu, S-X., Beran, M., Smith, T. L., Hester, J., Estey, E. H., and Benedict, W. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 84: 256-261, 1994.
17. Kornblau, S. M., Xu, H-J., del Giglio, A., Zhang, W., Calvert, L., Beran, M., Estey, E. H., Andreeff, M., Trujillo, J., Cork, M. A., Smith, T. L., Benedict, W. F., and Deisseroth, A. B. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res., 52: 4587-4590, 1992.
18. Snedecor, G. W., and Cochran, W. G. Statistical Methods. Ames, IA: Iowa State University Press, 1980.
19. 2 measures the discrepancy between observation and hypothesis. J. R. Stat. Soc., 87: 442-450, 1924.
20. Mehta, C. R. The exact analysis of contingency tables in medical research. Stat. Methods Med. Res., 3: 135-156, 1994.
21. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
22. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. J. R. Stat. Soc., 50: 163-170, 1966.
23. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
24. Fleming, T. R., and Harrington, D. P. Counting Processes and Survival Analysis. New York: Wiley, 1991.
25. Grambsch, P. C., and Therneau, T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 81: 515-526, 1994.
26. Cleveland, W. S. Robust locally-weighted regression and smoothing scatterplots. J. Am. Stat. Assoc., 74: 829-836, 1979.
27. Altman, D. G., Lausen, B., Sauerbrei, W., and Schumacher, M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J. Natl. Cancer Inst., 86: 829-835, 1994.
28. Schiffer, C. A., Lee, E., Tomiyasu, T., Wiernik, P., and Testa, J. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood, 73: 263-270, 1989.
29. Smith, T. L., McCredie, K. B., and Gehan, E. A. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia (Baltimore), 3: 257-263, 1989.
30. Keating, M. J., Cork, A., Broach, Y., Smith, T., Walters, R. S., McCredie, K. B., Trujillo, J., and Freireich, E. J. Toward a clinically relevant cytogenetic classification of AML. Leuk. Res., 11: 119-133, 1987.
31. Becker, R. A., Chambers, J. M., and Wilks, A. R. The New S Language. Pacific Grove, CA: Wadsworth, 1988.
32. Therneau, T. M. A Package for Survival Analysis in S. Rochester, MN: Mayo Clinic Foundation, 1994.
33. Lepelley, P., Soenen, V., Preudhomme, C., Merlat, A., Cosson, A., and Fenaux, P. bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia (Baltimore), 9: 726-730, 1995.
34. Delia, D., Aiello, A., Soligo, D., Fontanella, E., Melani, C., Pezzella, F., Pierotti, M. A., and Porta, G. D. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood, 79: 1291-1298, 1992.
35. Bensi, L., Longo, R., Vecchi, A., Messora, C., Garagnani, L., Bernardi, S., Tamassia, M. G., and Sacchi, S. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica, 80: 98-102, 1995.
36. Banker, D. E., Groudine, M., Norwood, T., and Appelbaum, F. R. Measurement of spontaneous and therapeutic agent-induced apoptosis with bcl-2 protein expression in acute myeloid leukemia. Blood, 89: 243-255, 1997.
37. Andreeff, M., Jiang, S., Zhang, X., Konopleva, M., Estrov, Z., Snell. V., Xie, Z., Okcu, M. F., Sanchez-Williams, G., Dong, J., Estey, E. H., Champlin, R. E., Kornblau, S. M., Reed, J. C., and Zhao, S. Expression of bcl-2 related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia (Baltimore), in press, 1999.
38. Estrov, Z., Thall, P., Talpaz, M., Estey, E. H., Kantarjian, H., Harris, D., Van, Q., Walterscheid, M., and Kornblau, S. M. Caspase 2 and Caspase 3 protein levels as predictors for survival in acute myelogenous leukemia. Blood, 92: 3090-9097, 1998.
39. Charpin, C., Garcia, S., Bonnier, P., Martini, F., Andrac, L., Horschowski, N., Lavaut, M-N., and Allasia, C. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. J. Clin. Oncol., 16: 2025-2031, 1998.
40. 1. Cancer Res., 58: 1609-1615, 1998.
41. Halder, S., Jena, N., and Croce, C. M. Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
42. Stoetzer, O. J., Nüssler, V., Darsow, M., Gullis, E., Pelka-Fleischer, R., Scheel, U., and Wilmanns, W. Association of bcl-2, bax, bcl-xL and interleukin-1b-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia (Baltimore), 10: S18-S22, 1996.
43. Ai, H-S., Re, W-N., Lu, S-J., and Lai, C-N. Expression of bcl-2 mRNA and bax mRNA in acute leukemia and leukemia cell lines. Blood, 90: 191b, 1997.
44. Andreeff, M., Zhao, S., Konopleva, M., Xie, Z., Zhang, X., Snell, V., McQueen, T., Jiang, S., Kliche, K-O., Schenk, T., Weidner, D., Estey, E. H., Thall, P., Sanchez-Williams, G., Kornblau, S. M., and Reed, J. C. The role of bcl-2 apoptosis regulating genes in acute myeloid leukemia. Blood, 90 (Suppl. 1): 66a, 1997.
45. Cheng, E. H. Y., Kirsch, D. G., Clem, R. J., Ravi, R., Kastan, M. B., Bedi, A., Ueno, K., and Hardwick, J. M. Conversion of bcl-2 to a bax-like death effector by caspases. Science (Washington DC), 278: 1966-1968, 1997.
46. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.